Last reviewed · How we verify
NCT06595160
Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
trial testing Non-Interventional Study in Borderline Resectable Pancreatic Ductal Adenocarcinoma in 87 participants. Currently enrolling.
30 April 2026
Quick facts
| Lead sponsor | Emory University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 87 |
| Start date | 5 August 2024 |
| Primary completion | 30 April 2026 |
| Estimated completion | 7 August 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Non-Interventional Study (non-interventional-study) — full drug profile →
Conditions studied
- Borderline Resectable Pancreatic Ductal Adenocarcinoma — all drugs for Borderline Resectable Pancreatic Ductal Adenocarcinoma →
- Resectable Pancreatic Ductal Adenocarcinoma — all drugs for Resectable Pancreatic Ductal Adenocarcinoma →
- Stage I Pancreatic Cancer AJCC v8 — all drugs for Stage I Pancreatic Cancer AJCC v8 →
Sponsor
Emory University
Who can join
18 and older, any sex, with Borderline Resectable Pancreatic Ductal Adenocarcinoma or Resectable Pancreatic Ductal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study explores the relationship between pre-treatment dietary patterns, fecal microbiome, and response to chemotherapy in patients with pancreatic ductal adenocarcinoma.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Unlocking the Potential of Bioactive Compounds in Pancreatic Cancer Therapy: A Promising Frontier.
Brugiapaglia S, Spagnolo F, Curcio C. · · 2025 · cited 1× · PMID 40427617 · DOI 10.3390/biom15050725 -
Strategic modulation of the gastrointestinal microbiome to enhance pancreatic cancer immunotherapy.
Jagwani S, Musumeci L, Flores L, Mackenzie GG, et al · · 2025 · PMID 41203044 · DOI 10.1016/j.drudis.2025.104528
Verify or expand the search:
- PubMed search for NCT06595160
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Non-Interventional Study
Trials testing the same drug.
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT07412002 — Quality of End-of-Life Care for Children With Cancer · not yet recruiting
- NCT06607874 — Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in · not yet recruiting
- NCT06630338 — Use of Shear Wave Elastography for Intraoperative Brain and Tumor Stiffness Measurements · not yet recruiting
- NCT07235501 — Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hemato · not yet recruiting
Other recruiting trials for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Currently open trials in the same condition.
- NCT06821997 — NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial · Phase 2 · recruiting
- NCT07269626 — PULSAR in Systemic Therapy for Pancreatic Cancer · Phase 2 · recruiting
- NCT06423326 — Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable · Phase 2 · recruiting
- NCT04005690 — Targeted Pathway Inhibition in Patients With Pancreatic Cancer · EARLY_PHASE1 · recruiting
Other Emory University trials
Trials by the same sponsor.
- NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
- NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
- NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
- NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
- NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06595160 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emory University
- Last refreshed: 1 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06595160.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing